

REMARKS

Currently claims 1-7 are pending. Applicants amend claims 4-5 to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 6-7 are cancelled herein as being in a form inappropriate to U.S. practice. Claims 8-39 are newly added and are supported by the disclosure on pages 15-17 of the application. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice. Accordingly, Claims 1-5 and 8-39 are before the Examiner for application.

Respectfully submitted,



John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: 4/8/05
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988